PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA.
about
Phosphoinositide 3-kinase: friend and foe in cardiovascular diseaseAerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAsRegulation of insulin and type 1 insulin-like growth factor signaling and action by the Grb10/14 and SH2B1/B2 adaptor proteinsmiRNome in myocardial infarction: Future directions and perspectiveIdentification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseasesVinculin directly binds zonula occludens-1 and is essential for stabilizing connexin-43-containing gap junctions in cardiac myocytesInsulin Signaling and Heart Failure.Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarctionSilencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.Identification of New SRF Binding Sites in Genes Modulated by SRF Over-Expression in Mouse HeartsPhosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure.Phosphorylated Grb14 is an endogenous inhibitor of retinal protein tyrosine phosphatase 1B, and light-dependent activation of Src phosphorylates Grb14.What do we know about the cardiac benefits of exercise?Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac ToxicityPhosphatase PTEN is critically involved in post-myocardial infarction remodeling through the Akt/interleukin-10 signaling pathway.Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kα signaling in cardiac hypertrophy.Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells.New frontiers in heart hypertrophy during pregnancy.Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart functionmiR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure OverloadMicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.Different roles of the cardiac Na+/Ca2+-exchanger in ouabain-induced inotropy, cell signaling, and hypertrophy.Spatial and temporal aspects and the interplay of Grb14 and protein tyrosine phosphatase-1B on the insulin receptor phosphorylation.Modulation of mouse rod photoreceptor responses by Grb14 protein.Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player.Can exercise teach us how to treat heart disease?The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.Therapeutic applications of PI3K inhibitors in cardiovascular diseases.The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy.Transcriptional assessment by microarray analysis and large-scale meta-analysis of the metabolic capacity of cardiac and skeletal muscle tissues to cope with reduced nutrient availability in Gilthead Sea Bream (Sparus aurata L.).MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3K p110δ).Human induced pluripotent stem cells derived under feeder-free conditions display unique cell cycle and DNA replication gene profiles.miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart FailuremiR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.Manipulation of cardiac phosphatidylinositol 3-kinase (PI3K)/Akt signaling by apoptosis regulator through modulating IAP expression (ARIA) regulates cardiomyocyte death during doxorubicin-induced cardiomyopathy.
P2860
Q26796228-0BE54EC5-EEC5-4565-960E-2DC0C37A3014Q26827482-1CF7C4E0-C036-4B9F-8A06-73E60B9B3852Q26849720-45745968-9925-4918-B2BD-8B45A7C60251Q27028108-685D920D-15A9-4CA2-B93B-0DF7997E3B50Q28583018-FEFF418B-C794-4881-8400-2D586AC58737Q28592273-CAF3A359-E26A-4BE7-8520-3624D81FC867Q30377910-75DBD2FD-D05A-4FA1-956D-6CBA2CBF7463Q35083679-FD94C368-39B1-405C-BACA-E56CC66B2451Q35108974-93F8A822-0604-4042-9B9F-90A1F32B23A4Q35118184-7FC9E792-B2D9-42E1-B787-9B87D46AB621Q35182995-B717CD21-E66B-4EBD-A4A9-1DBD5E9E479FQ35273915-878E7F97-4BC4-4C7F-A6C8-9F95EB703286Q35812621-86FB7697-B986-47FC-B376-19515936300DQ35999766-2F742313-138C-437E-8023-2026C3B6B23CQ36005489-30F411B3-9302-4041-B534-BC73501A9035Q36024414-8C13AAC6-55AC-4F5E-B136-F96EAA3D2B18Q36061754-3108C975-B3EC-4956-AFBC-961A8763EECBQ36135052-44E7B3A2-E634-4580-A372-6FEE7F3F8AEAQ36190273-314C2D40-4705-4240-B536-7AF7B717A4FBQ36378477-37E36CC7-12E6-408E-A8AA-F3C7ED892147Q36504308-95E9EA34-8210-49EA-90A9-7B3FB65AB3CCQ36634367-631C2663-72D8-4FDF-B576-665E1F327EFBQ37049227-7D695CAF-70EF-4FB4-8490-34B45850B5B4Q37175543-345CC25D-44A1-47DC-AD53-793E884F0F2EQ37426093-D564706D-E56C-4BBE-A5A9-D217F366194DQ37428661-DDFCAF25-B64C-4906-9B22-B22ED631AD4FQ37583782-F0EFB4EA-FFDC-4A62-ACD4-0D05D5B1F7E1Q37723852-E90E1DD2-05CF-494F-9E31-F14BC2F7BFAFQ37733708-4473F99D-2D44-4743-804F-B06A6233A044Q37833892-A014C15B-984D-4581-8EFB-26ED1F4847CEQ37868990-5D92BDCC-AC1D-4D25-8258-75B6BE021BE7Q38089742-65022C22-1665-4EBC-8264-711337124E0FQ38182139-BAD73304-F875-43B5-8DBC-25CD68337B8BQ38478822-6B708F17-53B2-46F7-B320-C86F7518BE64Q38492732-84E43AEC-ED30-43F1-96A4-65156FE36540Q38502628-90AF67C8-9BB2-453D-8CAE-C3DD7BE6B49EQ38591803-AA9D07B4-3B9C-4BDC-ABE3-E0006EAE202FQ38780801-190F6B4A-86D8-4E35-A990-CDF53821EAA5Q38796278-B3C37216-FE9B-4C77-B9C6-3AAB301857D3Q39043233-AD38DB13-384C-4105-A547-291763112D86
P2860
PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
PI3K(p110 alpha) protects agai ...... PI3K-regulated miRNA and mRNA.
@en
type
label
PI3K(p110 alpha) protects agai ...... PI3K-regulated miRNA and mRNA.
@en
prefLabel
PI3K(p110 alpha) protects agai ...... PI3K-regulated miRNA and mRNA.
@en
P2093
P50
P1476
PI3K(p110 alpha) protects agai ...... PI3K-regulated miRNA and mRNA.
@en
P2093
Elizabeth A Woodcock
Helen J Speirs
Helen Kiriazis
Ian W Dawes
Janelle P Mollica
Julie R McMullen
Mark A Febbraio
Rohan B H Williams
Ruby C Y Lin
Russell D Bouwman
P304
P356
10.1161/ATVBAHA.109.201988
P407
P577
2010-04-01T00:00:00Z